CL2022001739A1 - Compuestos tricíclicos sustituidos - Google Patents

Compuestos tricíclicos sustituidos

Info

Publication number
CL2022001739A1
CL2022001739A1 CL2022001739A CL2022001739A CL2022001739A1 CL 2022001739 A1 CL2022001739 A1 CL 2022001739A1 CL 2022001739 A CL2022001739 A CL 2022001739A CL 2022001739 A CL2022001739 A CL 2022001739A CL 2022001739 A1 CL2022001739 A1 CL 2022001739A1
Authority
CL
Chile
Prior art keywords
compound
formula
tricyclic compounds
rasopathies
disorders
Prior art date
Application number
CL2022001739A
Other languages
English (en)
Inventor
Pralhad Kurhade Sanjay
Sreedharan Nair Prathap
Sethi Sachin
Ramprasad Shukla Manojkumar
Dattatraya Sindkhedkar Milind
P Palle Venkata
Kumar Kamboj Rajender
Phukan Samiron
Rangrao Patil Pradeep
Majid Sayyed
Phadatare Ramesh
Walke Navnath
Pachpute Vipul
Gore Balasaheb
Tambe Vikas
Limaye Rohan
Bhosale Avadhut
Mahangare Sachin
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CL2022001739A1 publication Critical patent/CL2022001739A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan compuestos de fórmula general (I), su forma tautomérica, su estereoisómero, su sal farmacéuticamente aceptable, su polimorfo o solvato del mismo, en donde, el anillo A, el anillo B, de R1 a R4 , y n son como se definen en 10 el presente documento, para usar como inhibidores de SOS1 en el tratamiento de enfermedades o trastornos proliferativos, infecciosos y RASopatías. También se divulgan métodos para sintetizar el compuesto de fórmula I, composiciones farmacéuticas que contienen el compuesto de fórmula I, método de tratamiento de enfermedades o trastornos proliferativos, infecciosos y RASopatías, por 15 ejemplo, un cáncer, administrando dicho compuesto y combinaciones del compuesto de fórmula I con otros principios activos.
CL2022001739A 2019-12-27 2022-06-23 Compuestos tricíclicos sustituidos CL2022001739A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201921054254 2019-12-27
IN201921049099 2019-12-29
IN202021022668 2020-05-29
IN202021032769 2020-07-30
IN202021035200 2020-08-14

Publications (1)

Publication Number Publication Date
CL2022001739A1 true CL2022001739A1 (es) 2023-03-31

Family

ID=74184675

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001739A CL2022001739A1 (es) 2019-12-27 2022-06-23 Compuestos tricíclicos sustituidos

Country Status (16)

Country Link
US (1) US20230119316A1 (es)
EP (1) EP4081521A1 (es)
JP (1) JP2023514019A (es)
KR (1) KR20220132543A (es)
AU (1) AU2020412429A1 (es)
BR (1) BR112022012641A2 (es)
CA (1) CA3165864A1 (es)
CL (1) CL2022001739A1 (es)
CO (1) CO2022010460A2 (es)
CR (1) CR20220363A (es)
EC (1) ECSP22058816A (es)
IL (1) IL294198A (es)
MX (1) MX2022008066A (es)
PE (1) PE20221283A1 (es)
WO (1) WO2021130731A1 (es)
ZA (1) ZA202207722B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11964977B2 (en) 2020-05-29 2024-04-23 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic heterocyclic compounds

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4214209A1 (en) 2020-09-15 2023-07-26 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
CN116568681A (zh) * 2020-12-07 2023-08-08 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
CR20230402A (es) * 2021-01-19 2023-11-21 Lupin Ltd Combinaciones farmacéuticas de inhibidores de sos1 para tratar o prevenir cancer
CN114835719A (zh) * 2021-02-01 2022-08-02 苏州泽璟生物制药股份有限公司 取代双环并芳杂环胺类抑制剂及其制备方法和应用
WO2022207673A1 (en) 2021-03-31 2022-10-06 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
JP2024514127A (ja) 2021-04-09 2024-03-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん剤療法
TWI807787B (zh) * 2021-04-19 2023-07-01 大陸商昆藥集團股份有限公司 苯並嘧啶三環衍生物及製備方法和應用
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN115536660A (zh) * 2021-11-04 2022-12-30 北京福元医药股份有限公司 苄氨基取代的杂多环化合物及其组合物、制剂和用途
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
CN116265462A (zh) * 2021-12-17 2023-06-20 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
WO2023135260A1 (en) 2022-01-14 2023-07-20 Jazz Pharmaceuticals Ireland Limited Novel amine-substituted phthalazines and derivatives as sos1 inhibitors
KR20230121208A (ko) * 2022-02-10 2023-08-18 (주)파로스아이바이오 Sos1 억제제 및 이의 유도체
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023165438A1 (zh) * 2022-03-03 2023-09-07 浙江海正药业股份有限公司 三环类衍生物及其制备方法和用途
GB202203976D0 (en) 2022-03-22 2022-05-04 Jazz Pharmaceuticals Ireland Ltd Tricyclic phthalazines and derivatives as sos1 inhibitors
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5661147A (en) * 1993-09-03 1997-08-26 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
TW372967B (en) 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof
AU2003256323A1 (en) 2002-06-26 2004-01-19 Chiron Corporation Sos1 inhibitors
US8039506B2 (en) 2006-12-20 2011-10-18 Bristol-Myers Squibb Company Bicyclic lactam factor VIIa inhibitors useful as anticoagulants
US8389511B2 (en) 2007-12-19 2013-03-05 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic derivative
WO2009106599A2 (en) 2008-02-29 2009-09-03 Novartis Ag Substituted piperidines as therapeutic compounds
CN102633812B (zh) * 2012-04-06 2014-11-12 中国药科大学 噁唑酮并喹唑啉衍生物、制备方法及用途
US10087215B2 (en) 2013-03-15 2018-10-02 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
HUE061770T2 (hu) 2014-04-23 2023-08-28 Incyte Holdings Corp 1H-pirrolo[2,3-C]piridin-7(6H)-onok és pirazolo[3,4-C]piridin-7(6H)-onok mint BET fehérjék gátlószerei
WO2016077793A1 (en) 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
TW201711999A (zh) 2015-09-03 2017-04-01 佛瑪治療公司 ﹝６，６﹞稠合雙環組蛋白脫乙醯基酶８（ｈｄａｃ８）抑制劑
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
JOP20190221A1 (ar) 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
EA202091491A1 (ru) 2017-12-21 2020-11-13 Бёрингер Ингельхайм Интернациональ Гмбх Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
CA3097231A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
CN113767100A (zh) 2019-03-01 2021-12-07 锐新医药公司 双环杂芳基化合物及其用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11964977B2 (en) 2020-05-29 2024-04-23 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic heterocyclic compounds

Also Published As

Publication number Publication date
MX2022008066A (es) 2022-08-15
CN115605476A (zh) 2023-01-13
US20230119316A1 (en) 2023-04-20
AU2020412429A1 (en) 2022-08-18
JP2023514019A (ja) 2023-04-05
EP4081521A1 (en) 2022-11-02
IL294198A (en) 2022-08-01
PE20221283A1 (es) 2022-09-05
BR112022012641A2 (pt) 2022-09-06
KR20220132543A (ko) 2022-09-30
CR20220363A (es) 2022-09-23
WO2021130731A1 (en) 2021-07-01
ZA202207722B (en) 2023-03-29
ECSP22058816A (es) 2022-08-31
CO2022010460A2 (es) 2022-08-09
CA3165864A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
CL2021000737A1 (es) Fabricación de compuestos y composiciones para inhibir la actividad de shp2
ECSP22077299A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
CL2020001343A1 (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
ECSP22019360A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
CO2022002729A2 (es) Métodos de tratamiento del cáncer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrógenos
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
UY39261A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
AR127470A1 (es) Inhibidores de lrrk2
UY37569A (es) Inhibidores del inmunoproteasoma
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
BR112020026507A8 (pt) Composto de isotiazolo[5,4-d]pirimidinas como inibidor de irak4